Nasal delivery of oxytocin

Patent metadata

Field	Value
Publication number	US-11291626-B2
Application number	US-201113823071-A
Country	US
Kind code	B2
Filing date	Sep 14, 2011
Priority date	Sep 14, 2010
Publication date	Apr 5, 2022
Grant date	Apr 5, 2022

Abstract

A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.

First claim

The invention claimed is:

1. A method of treating autism or schizophrenia, consisting of:
a first step and, separately, a second step;
wherein the first step includes delivering a first substance to the upper posterior, olfactory region of a nasal airway of a subject, which includes the olfactory bulb and the trigeminal nerve of the subject, wherein the first substance comprises between 1 IU and 15 IU of oxytocin; and
wherein the second step includes delivering a second substance to promote transfer of the first substance, wherein the second substance is a liquid and delivered after the first substance.

2. The method of claim 1 , wherein the first substance is a powder.

3. The method of claim 2 , wherein the first substance is mixed with a bulking agent.

4. The method of claim 1 , wherein the first substance is a liquid.

5. The method of claim 1 , wherein the first substance includes a thickening agent, which thickens on exposure to moisture.

6. The method of claim 5 , wherein the thickening agent comprises one or more of pectin, agar-agar, lignin, algin, gums and cellulose.

7. The method of claim 1 , wherein the first substance is administered once daily.

8. The method of claim 1 , wherein the first substance is administered twice daily.

9. The method of claim 1 , wherein the delivery of the first substance is targeted to provide for one or both of nose-to-brain (N2B) and systemic delivery of the first substance.

10. The method of claim 9 , wherein the delivery is targeted to provide for both nose-to-brain (N2B) and systemic delivery of the first substance, and the first substance is formulated to provide for greater N2B delivery than systemic delivery of the first substance.

11. The method of claim 9 , wherein the delivery of the first substance is targeted to provide for both nose-to-brain (N2B) and systemic delivery, and the first substance is formulated to provide for greater systemic delivery than N2B delivery of the first substance.

12. The method of claim 1 , wherein the first substance further comprises a decongestant.

13. The method of claim 1 , wherein the first substance comprises less than about 10 IU of oxytocin.

14. The method of claim 1 , wherein the first substance comprises less than about 5 IU of oxytocin.

15. The method of claim 1 , wherein the first substance comprises from about 1 IU to about 10 IU of oxytocin.

16. The method of claim 1 , wherein the first substance comprises from about 3 IU to about 10 IU of oxytocin.

17. The method of claim 1 , wherein the first substance comprises from about 3 IU to about 5 IU of oxytocin.

18. The method of claim 1 , wherein the oxytocin of the first substance is a first active ingredient and wherein the first substance includes a second active ingredient.

19. A method of treating autism or schizophrenia, consisting of:
a first step and, separately, a second step;
wherein the first step includes delivering a first substance to the upper posterior, olfactory region of a nasal airway of a subject, which includes the olfactory bulb and the trigeminal nerve of the subject, wherein the first substance comprises between 1 IU and 5 IU of oxytocin; and
wherein the second step includes delivering a second substance to promote transfer of the first substance, wherein the second substance is a liquid and delivered after the first substance.

Assignees

• Djupesland Per Gisle
• Optinose As

Inventors

• Djupesland Per Gisle

Classifications

• A61M15/0091 Primary

  mechanically breath-triggered · CPC title

• A61K31/551

  having two nitrogen atoms, e.g. dilazep · CPC title

• A61M2202/0468

  non-physiological · CPC title

• A61M2205/59

  Aesthetic features, e.g. distraction means to prevent fears of child patients · CPC title

• A61M15/0098

  Activated by exhalation · CPC title